Clarity Pharmaceuticals Ltd (ASX:CU6)

Market Cap	578.28M -65.5%
Revenue (ttm)	10.53M +11.2%
Net Income	-107.24M
EPS	-0.29
Shares Out	373.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,714,069
Open	1.590
Previous Close	1.575
Day's Range	1.550 - 1.630
52-Week Range	1.515 - 5.140
Beta	1.18
Analysts	Strong Buy
Price Target	7.20 (+364.19%)
Est. Earnings	Nov 26, 2026

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 100
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CU6

Financial Performance

In fiscal year 2026, Clarity Pharmaceuticals's revenue was 10.53 million, an increase of 11.24% compared to the previous year's 9.46 million. Losses were -107.24 million, 66.8% more than in 2025.

Analyst Summary

According to 4 analysts, the average rating for CU6 stock is "Strong Buy." The 12-month stock price target is $7.20, which is an increase of 364.19% from the latest price.

Price Target

$7.20

(364.19% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 27, 2026

Data Sources Report a data error